


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously Presented) An indole compound represented by the formula (I), or a pharmaceutically acceptable salt, solvate, or prodrug thereof;




wherein ;

R₁ is (c) wherein;

(c) is the group $-(L_1)-R_{11}$; where, $-(L_1)-$ is a divalent linking group of 1 to 8 atoms and where R_{11} is $-(CH_2)_m-R_{12}$;


R₂ is hydrogen, or C1-C4 alkyl;

R₃ is $-(L_3)-Z$, where $-(L_3)-$ is a divalent linker group selected from a bond or:



-CH₂-

and Z is a group represented by the formulae,



wherein, X is oxygen or sulfur; and R_a is selected from hydrogen, C₁-C₈ alkyl, aryl, C₁-C₈ alkaryl, C₁-C₈ alkoxy, aralkyl and -CN;

R₄ is the group, -(L_h)-(hydroxyfunctional amide); wherein -(L_h)-, is an hydroxyfunctional amide linker having an hydroxyfunctional amide linker length of 1 to 8;


R₅ is selected from hydrogen, a non-interfering substituent, or the group, -(L_a)-(acidic group); wherein -(L_a)-, is an acid linker having an acid linker length of 1 to 8;


R₆ and R₇ are selected from hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, and C₂-C₆ alkynyl.

2. (Previously Presented) The compound of claim 1 wherein R₂ is hydrogen, C₁-C₄ alkyl, C₂-C₄ alkenyl, -O-(C₁-C₃ alkyl), -S-(C₁-C₃ alkyl), and C₃-C₄ cycloalkyl.

3. (Cancelled)

4. (Previously Presented) The compound of Claim 1 wherein the hydroxyfunctional amide linker group, -(L_h)-, for R₄ is a divalent group selected from,





where R₄₀, R₄₁, R₄₂, and R₄₃ are each independently selected from hydrogen, C₁-C₈ alkyl.

5. (Cancelled)

6. (Previously Presented) The compound of claim 1 wherein R₅ is the group, -(L_a)-(acidic group) and wherein the (acidic group) is:




7. (Cancelled)

8. (Cancelled)

9. (Cancelled)

10. (Original) The compound of claim 1 wherein for R₃, Z is the group represented by the formula;



and the linking group -(L₃)- is a bond.

11. (Cancelled)

12. (Cancelled)

13. (Cancelled)


14. (Cancelled)

15. (Cancelled)

16. (Cancelled)

17. (Cancelled)

18. (Original) The compound of claim 1 wherein R₄ is the group, -(L_C)-(hydroxyfunctional amide group) and wherein the (hydroxyfunctional amide group) is:



and R^{4a} is independently selected from the group consisting of OH, (C₁-C₆)alkoxy, (C₇-C₁₄)alkaryloxy, (C₂-C₈)alkenyloxy, (C₇-C₁₄) aralkyloxy, (C₇-C₁₄)aralkenyloxy and aryloxy; and

wherein R^{4b} is independently selected from the group consisting of H, (C₁-C₆)alkyl, arylalkyl, heteroaryl and aryl.

19. (Cancelled)

20. (Previously Presented) A compound selected from the group of:

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(hydroxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(methyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(methyl)-N-(methyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(hydroxy)-N-(methyl)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(ethyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(2-propenyloxy)acetamide;
2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(hydroxy)-N-(2-propyl)acetamide;
2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(tert-butyloxy)acetamide;
2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-[2-(methyl)propyloxy]acetamide;
2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(phenylmethyloxy)acetamide;
2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(methyl)-N-(phenylmethyloxy)acetamide;
2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(phenyloxy)acetamide;
2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(methyl)-N-(phenyloxy)acetamide;
2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(cyclohexyl)-N-(hydroxy)acetamide; and
2-[[3-(2-Amino-2-oxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(hydroxy)acetamide.

21. (Cancelled)

22. (Original) A pharmaceutical formulation comprising a indole compound as claimed in claim 1 together with a pharmaceutically acceptable carrier or diluent therefor.

23. (Cancelled)

24. (Cancelled)

25. (Previously Presented) A pharmaceutical formulation containing an effective amount of the compound of claim 1 useful for the treatment and/or amelioration of Inflammatory Diseases.

26. (Cancelled)

Serial No. 10/629,992

27. (Cancelled)